Manuel Ramos-Casals
Overview
Explore the profile of Manuel Ramos-Casals including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
227
Citations
8297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chanson N, Galvagni A, Ramos-Casals M, Ruiz J, Suijkerbuijk K, Benesova K, et al.
Rheumatology (Oxford)
. 2024 Dec;
PMID: 39714261
Objective: To describe presentation, treatment and outcome of immune checkpoint inhibitor (ICI) associated-vasculitis in cancer patients in a multicentre study. Methods: Thanks to the ImmunoCancer International Registry (ICIR), a multidisciplinary...
2.
Brito-Zeron P, Flores-Chavez A, Gonzalez-de-Paz L, Feijoo-Masso C, de Escalante B, Gonzalez-Garcia A, et al.
Postgrad Med J
. 2024 Jul;
100(1190):898-907.
PMID: 38972066
Purpose: To investigate the phenotype of sarcoidosis according to the time when a malignancy is diagnosed (preexisting to the diagnosis of sarcoidosis, concomitant, or sequential) and to identify prognostic factors...
3.
Ramos-Casals M, Siso-Almirall A
Ann Intern Med
. 2024 Feb;
177(2):ITC17-ITC32.
PMID: 38346306
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any...
4.
Flores-Chavez A, Brito-Zeron P, Ng W, Szanto A, Rasmussen A, Priori R, et al.
Clin Exp Rheumatol
. 2023 Nov;
41(12):2437-2447.
PMID: 38019164
Objectives: To analyse how the key components at the time of diagnosis of the Sjögren's phenotype (epidemiological profile, sicca symptoms, and systemic disease) can be influenced by the potential exposure...
5.
Brito-Zeron P, Flores-Chavez A, Ng W, Horvath I, Rasmussen A, Priori R, et al.
Clin Exp Rheumatol
. 2023 Nov;
41(12):2448-2457.
PMID: 38019154
Objectives: To analyse how the potential exposure to air pollutants can influence the key components at the time of diagnosis of Sjögren's phenotype (epidemiological profile, sicca symptoms, and systemic disease)....
6.
Brito-Zeron P, Lower E, Ramos-Casals M, Baughman R
Expert Rev Clin Immunol
. 2023 Oct;
20(1):59-70.
PMID: 37878359
Introduction: We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies. Areas Covered: Theetiology of cytopenias in sarcoidosis...
7.
Brito-Zeron P, Flores-Chavez A, Horvath I, Rasmussen A, Li X, Olsson P, et al.
EClinicalMedicine
. 2023 Jul;
61:102062.
PMID: 37457113
Background: What baseline predictors would be involved in mortality in people with primary Sjögren syndrome (SjS) remains uncertain. This study aimed to investigate the baseline characteristics collected at the time...
8.
Flores-Chavez A, Brito-Zeron P, Retamozo S, Bitoun S, Fisher B, Liew D, et al.
Crit Rev Immunol
. 2023 Apr;
42(4):21-36.
PMID: 37022357
Immunotherapies, such as immune checkpoint inhibitors (ICIs), have significantly advanced the treatment of cancer and other conditions. However, these therapies can also cause immune-related adverse events (irAEs), which are unintended...
9.
Brito-Zeron P, Perez-Alvarez R, Ramos-Casals M
Med Clin (Barc)
. 2023 Jan;
160(6):278.
PMID: 36707372
No abstract available.
10.
Flores-Chavez A, Ng W, Alunno A, Inanc N, Feijoo-Masso C, Seror R, et al.
Clin Exp Rheumatol
. 2022 Dec;
40(12):2329-2337.
PMID: 36541233
Objectives: To characterise the key epidemiological, clinical, immunological, imaging, and pathological features of the coexistence between sarcoidosis and Sjögren's syndrome (SS). Methods: All centres included in two large multicentre registries...